24/04/2014 07:06:43 Free Membership Login

UPDATE:FDA Approves Generic Versions Of Blood-Thinning Drug Plavix

Date : 05/17/2012 @ 3:55PM
Source : Dow Jones News
Stock : Sanofi (SAN)
Quote : 77.29  0.24 (0.31%) @ 6:51AM
Sanofi share price Chart

UPDATE:FDA Approves Generic Versions Of Blood-Thinning Drug Plavix

Bristol Myers Sqibb (NYSE:BMY)
Historical Stock Chart

2 Years : From Apr 2012 to Apr 2014

Click Here for more Bristol Myers Sqibb Charts.

The U.S. Food and Drug Administration on Thursday approved generic versions of blood-thinning drug Plavix.

Plavix, marketed by Bristol-Myers Squibb Co. (BMY) and Sanofi (SNY), is used to ward off heart attacks and strokes in people with cardiovascular disease, and was among the best-selling drugs in history. The drug's $6.8 billion in U.S. sales last year, as tallied by IMS Health, ranked second behind Pfizer Inc.'s (PFE) Lipitor, which is used to treat high cholesterol. Plavix's U.S. patent expired Thursday, clearing the way for generic versions of the drug, which carries the generic name clopidogrel.

The FDA said it approved Dr. Reddy's Laboratories Ltd. (RDY, 500124.BY), Gate Pharmaceuticals, Mylan Pharmaceuticals and Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) to sell a 300-milligram dose of clopidogrel. Teva and Mylan have also been granted approval to sell a 75-milligram dose of the drug along with Apotex Inc., Aurobindo Pharma Ltd. (524804.BY), Roxane Laboratories, Sun Pharmaceutical Industries Ltd. (524715.BY), and Torrent Pharmaceuticals Ltd. (500420.BY).

Clopidogrel is FDA-approved to treat patients who have recently had a heart attack or stroke, or have partial or total blockage of an artery, the FDA said.

In a statement, Mylan said it would beginning shipping both doses of clopidogrel immediately. The company also said it had 180 days of exclusivity to sell the 300-milligram version of clopidogrel because it was the first company to file for FDA approval of that dose.

Bristol-Myers Squibb and Sanofi are offering discounts to patients who want to continue using branded Plavix.

Bristol and Sanofi are offering a Plavix Choice Program to cap monthly, out-of-pocket costs to $37 starting Thursday.

Without the discount, monthly out-of-pocket costs could rise to $100 for branded Plavix due to changes by health plans designed to encourage use of generic Plavix. The program is open to eligible cash-paying and commercially insured patients. Patients can choose to receive the drug at a pharmacy or have it shipped directly.

Bristol-Myers said it's not widely promoting Plavix Choice, but has reached out to current Plavix patients to let them know it's available.

"It is a program that BMS and Sanofi are providing for patients who wish to continue on brand-name Plavix once generics become available," said Bristol spokeswoman Laura Hortas.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

-Peter Loftus contributed to this article.



NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us 140424 07:06